These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 10597732)

  • 41. Sequential combinations of flavopiridol and docetaxel inhibit prostate tumors, induce apoptosis, and decrease angiogenesis in the Ggamma/T-15 transgenic mouse model of prostate cancer.
    Reiner T; de las Pozas A; Perez-Stable C
    Prostate; 2006 Oct; 66(14):1487-97. PubMed ID: 16921509
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of cytotoxic chemotherapy in prostate cancer. A critical reevaluation 20 years later.
    Eisenberger MA; Sinibaldi VW
    Oncology (Williston Park); 2006 Jul; 20(8):853-62; discussion 863, 867-8. PubMed ID: 16922258
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets.
    Ioannidou E; Moschetta M; Shah S; Parker JS; Ozturk MA; Pappas-Gogos G; Sheriff M; Rassy E; Boussios S
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576107
    [TBL] [Abstract][Full Text] [Related]  

  • 44. When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?
    Hamberg P; Verhagen PC; de Wit R
    Eur J Cancer; 2008 Jun; 44(9):1193-7. PubMed ID: 18448326
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical trials in metastatic prostate cancer--has there been real progress in the past decade?
    Bhandari MS; Petrylak DP; Hussain M
    Eur J Cancer; 2005 Apr; 41(6):941-53. PubMed ID: 15808960
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer.
    Uzzo RG; Haas NB; Crispen PL; Kolenko VM
    Cancer; 2008 Apr; 112(8):1660-71. PubMed ID: 18278811
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical trials referral resource. Clinical trials of flavopiridol.
    Wright J; Blatner GL; Cheson BD
    Oncology (Williston Park); 1998 Jul; 12(7):1018, 1023-4. PubMed ID: 9684276
    [No Abstract]   [Full Text] [Related]  

  • 48. Novel strategies and therapeutics for the treatment of prostate carcinoma.
    Morris MJ; Scher HI
    Cancer; 2000 Sep; 89(6):1329-48. PubMed ID: 11002230
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prostate cancer: horizons in the development of novel anti-cancer strategies.
    Papatsoris AG; Papavassiliou AG
    Curr Med Chem Anticancer Agents; 2001 May; 1(1):47-70. PubMed ID: 12678770
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
    Ozkan EE
    Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Second-line chemotherapy for advanced hormone-refractory prostate cancer.
    Garmey EG; Sartor O; Halabi S; Vogelzang NJ
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):118-22, 127-32. PubMed ID: 18347563
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.
    Nguyen DM; Schrump WD; Tsai WS; Chen A; Stewart JH; Steiner F; Schrump DS
    J Thorac Cardiovasc Surg; 2003 May; 125(5):1132-42. PubMed ID: 12771887
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis.
    Pili R; Kruszewski MP; Hager BW; Lantz J; Carducci MA
    Cancer Res; 2001 Feb; 61(4):1477-85. PubMed ID: 11245454
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Progress of molecular targeted therapies for prostate cancers.
    Fu W; Madan E; Yee M; Zhang H
    Biochim Biophys Acta; 2012 Apr; 1825(2):140-52. PubMed ID: 22146293
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New molecular targets in advanced prostate cancer.
    Dawson NA
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):993-1002. PubMed ID: 16831072
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation.
    Rahman KM; Banerjee S; Ali S; Ahmad A; Wang Z; Kong D; Sakr WA
    Cancer Res; 2009 May; 69(10):4468-75. PubMed ID: 19435906
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel therapeutic strategies for androgen-independent prostate cancer: an update.
    Assikis VJ; Simons JW
    Semin Oncol; 2004 Apr; 31(2 Suppl 4):26-32. PubMed ID: 15124131
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antimetastatic drugs in prostate cancer.
    Chay CH; Cooper CC; Hellerstedt BA; Pienta KJ
    Clin Prostate Cancer; 2002 Jun; 1(1):14-9. PubMed ID: 15046708
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Approaches to inhibit invasiveness and metastasis in prostate cancer.
    Posadas EM; Dahut WL
    Clin Prostate Cancer; 2002 Sep; 1(2):125. PubMed ID: 15046704
    [No Abstract]   [Full Text] [Related]  

  • 60. Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies.
    Morris MJ; Scher HI
    Surg Oncol; 2002 Jun; 11(1-2):13-23. PubMed ID: 12031864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.